{"organizations": [], "uuid": "d22b14a706bc8f5d292ebcde4f977c70a5a95f75", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "https://images.wsj.net/im-9828/social", "site_section": "https://www.wsj.com/europe", "section_title": "The Wall Street Journal &amp; Breaking News, Business, Financial and Economic News, World News and Video", "url": "https://www.wsj.com/articles/shire-investors-can-profit-from-takeda-skepticism-1525795630", "country": "US", "domain_rank": 387, "title": "Shire Investors Can Profit From Takeda Skepticism", "performance_score": 0, "site": "wsj.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-08T20:07:00.000+03:00", "replies_count": 0, "uuid": "d22b14a706bc8f5d292ebcde4f977c70a5a95f75"}, "author": "Charley Grant", "url": "https://www.wsj.com/articles/shire-investors-can-profit-from-takeda-skepticism-1525795630", "ord_in_thread": 0, "title": "Shire Investors Can Profit From Takeda Skepticism", "locations": [], "entities": {"persons": [{"name": "tak", "sentiment": "negative"}, {"name": "takeda", "sentiment": "none"}, {"name": "shire", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "japan", "sentiment": "none"}], "organizations": [{"name": "shire investors can profit from takeda", "sentiment": "negative"}, {"name": "shire", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Making a $62 billion acquisition work for your investors isnâ€™t easy, but the odds of success for Takeda Pharmaceuticals with Shire are higher than the market currently thinks.\nThe cash and stock deal will solve a major strategic problem for Takeda since drug sales in Japan are falling due to an aging population and fairly strict government regulations on drug prices. Shire books a majority of its sales in the U.S., where the long term industry outlook is brighter and pricing is more permissive.\n... ", "external_links": [], "published": "2018-05-08T20:07:00.000+03:00", "crawled": "2018-05-08T23:52:09.042+03:00", "highlightTitle": ""}